P1049: A PHASE 2 STUDY OF BEZUCLASTINIB (CGT9486), A NOVEL, HIGHLY SELECTIVE, POTENT KIT D816V INHIBITOR, IN ADULTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS (APEX): METHODS, BASELINE DATA, AND EARLY INSIGHTS

• D. J. DeAngelo,
• V. Pullarkat,
• M. Piris-Villaespesa,
• T. I. George,
• J. L. Patel,
• C. Ustun,
• P. Bose,
• M. L. Heaney,
• A. Pilla,
• M. Massaro,
• B. Exter,
• H. A. Jolin,
• Z. Mikhak,
• T. Tashi

Affiliations

D. J. DeAngelo

1 Dana-Farber Cancer Institute, Boston

V. Pullarkat

2 City of Hope, Duarte, United States of America

M. Piris-Villaespesa

3 Hospital Universitario Ramón y Cajal, Madrid, Spain

T. I. George

4 ARUP Laboratories

J. L. Patel

4 ARUP Laboratories

C. Ustun

6 Rush University Cancer Center, Chicago

P. Bose

7 The University of Texas MD Anderson Cancer Center, Houston

M. L. Heaney

8 Columbia University Medical Center, New York

A. Pilla

9 Cogent Biosciences, Cambridge, United States of America

M. Massaro

9 Cogent Biosciences, Cambridge, United States of America

B. Exter

9 Cogent Biosciences, Cambridge, United States of America

H. A. Jolin

9 Cogent Biosciences, Cambridge, United States of America

Z. Mikhak

9 Cogent Biosciences, Cambridge, United States of America

T. Tashi

5 Huntsman Cancer Institute, University of Utah, Salt Lake City